Advanced Tests for Cancer Diagnosis and Monitoring
In the fight against cancer, early and highly accurate diagnosis is the foundation of effective treatment and a better life. Our hub offers the most advanced molecular and genetic tests, capable of identifying tumors as small as 1 mm — well below the limit detectable by CT or MRI — and providing a detailed assessment of the evolution of different forms of cancer.
Discover innovative solutions for cancer detection and monitoring, tailored to your specific needs, for a healthier future.
General Detection
An innovative test for the early detection of multiple types of cancer through a simple blood test. TruCheck™ offers a non-invasive and accurate solution for identifying signs of cancer in its early stages.
Specific Diagnostics
Advanced analysis for specific cancer confirmation and diagnosis. TruBlood uses state-of-the-art technologies to provide clear, fast and reliable results, supporting doctors in determining the optimal treatment.
Tumor Analysis & Chemosensitivity
Personalized test that evaluates tumor profile and sensitivity to chemotherapy. Exacta & Chemo-Saale helps choose the most effective therapeutic plan, reducing side effects and increasing the chances of treatment success.
Progress Monitoring
Dedicated solution for monitoring patient progress during treatment. Cancertrack provides precise information on response to therapy and detects potential recurrences, ensuring optimal long-term disease control.
FAQ's
We offer a full range of tests, including Trucheck™ for multi-cancer screening, Trublood™ and Celldx™ for diagnosis and detection, Exata™ and Chemo-scale® for guidance and treatment, and Cancertrack™ for post-treatment monitoring.
Our tests, such as Trucheck™ and Trublood™, use analyses of circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) to detect signs of cancer without invasive procedures.
The tests are designed to meet the diverse needs of patients, from asymptomatic individuals to those with familial risks, patients avoiding invasive biopsies, and those requiring post-treatment monitoring.
Early detection is essential to improve prognosis and reduce the chances of recurrence, allowing for more effective and faster interventions.
Detailed genomic analysis, as performed in the Celldx™ test, helps identify personalized treatments based on the tumor's specific molecular profile.
